EUTM file information

018530832

BIOBETTER

August 8, 2021

Trademark Summary

The trademark application BIOBETTER was filed by BIOBETTER LTD., a corporation established under the laws of the State of Israel (the "Applicant"). Application refused.

The application was filed in Danish (English was selected as the second language).

The Refusal with reference B 018530832 was Rejected according to Article 7(1)(b) EUTMR with decision issued on March 30, 2022 by the EUIPO.

Goods And Services

  • The mark was filed in class 5 with following description of goods:
    1. Biological preparations for the treatment of inflammatory conditions and oncological conditions
    2. Chemical preparations for pharmaceutical or medical purposes, namely, for treating inflammatory conditions, oncological conditions
    3. Antibiotics
    4. Anti-infectives
    5. Anti-virals
    6. Pharmaceutical Medicinal Preparations in Liquid, Tablet, Capsule, Powder, Ointment, Cream, and Dosage Forms, for Oral, Parenteral, and Topical Administration for the treatment of cardiovascular disorders, artheriosclerotic diseases and autoimmune diseases
    7. Pharmaceutical Medicinal Preparations in Liquid, Tablet, Capsule, Powder, Ointment, Cream, and Dosage Forms, for Oral, Parenteral, and Topical Administration for the treatment of central nervous system diseases and disorders, cerebrovascular diseases, diabetes and other metabolic disorders
    8. Pharmaceutical Medicinal Preparations in Liquid, Tablet, Capsule, Powder, Ointment, Cream, and Dosage Forms, for Oral, Parenteral, and Topical Administration for the treatment of inflammation and inflammatory diseases, respiratory and infectious diseases, peripheral and central vascular diseases and metabolic disorders
    9. Pharmaceutical Medicinal Preparations in Liquid, Tablet, Capsule, Powder, Ointment, Cream, and Dosage Forms, for Oral, Parenteral, and Topical Administration for the treatment of seizure disorders, shock and central nervous system trauma, stroke, and viral diseases
    10. Pharmaceutical products for the treatment of cardiovascular disorders, artheriosclerotic diseases and autoimmune diseases
    11. Pharmaceutical products for the treatment of central nervous system diseases and disorders, cerebrovascular diseases, diabetes and other metabolic disorders
    12. Pharmaceutical products for the treatment of inflammation and inflammatory diseases, respiratory and infectious diseases, peripheral and central vascular diseases and metabolic disorders
    13. Pharmaceutical products for the treatment of seizure disorders, shock and central nervous system trauma, stroke, and viral diseases.